KR20240006283A - A composition for improving, preventing and treating of depression containing Eriobotrya japonica fruit extract - Google Patents

Abstract

The present invention relates to a composition for improving, preventing or treating depression caused by stress, and can improve, prevent or treat depression caused by stress by containing extract of loquat trees ( Eriobotrya japonica ) fruit as an active ingredient. Additionally, since it is non-toxic, it can be consumed in food form.

Description

A composition for improving, preventing and treating depression containing loquat tree fruit extract as an active ingredient {A composition for improving, preventing and treating of depression containing Eriobotrya japonica fruit extract}

The present invention relates to a composition that can improve, prevent, or treat depression by containing loquat tree fruit extract as an active ingredient.

As society develops and diversifies rapidly, modern people are required to take on various roles. Accordingly, the number of people complaining of mental illnesses such as depression, anxiety disorders, or sleep disorders caused by various types of stress is increasing. According to the 2006 epidemiological survey on mental disorders conducted by the Ministry of Health and Welfare on adults aged 18 to 64, the 'one-year prevalence rate of mental disorders' was found to be 17.1%.

In addition, the 'lifetime prevalence of mental illness', which is the proportion of the population experiencing at least one mental illness during their lifetime, was found to be 30%, or 1 in 3 adults (as of 2006). In addition, mental illness in adolescents has recently been on the rise due to causes such as excessive academic enthusiasm.

Stress is a feeling of anxiety and threat that a person feels when faced with a situation that is psychologically or physically difficult to handle. No one can avoid stress because this type of stress exists in all areas of human life. When humans are in a stressful situation, the sympathetic part of the autonomic nervous system is activated as a physical response to stress, and the body's resources are mobilized to respond to the emergency situation.

If stress is not dealt with and left untreated, psychological reactions such as depression, anxiety, fatigue, anger, and mood changes result, as well as physiological reactions such as a decrease in α-waves among brain waves and an increase in blood pressure and pulse rate. If this happens over and over again, it causes diseases such as depression, anxiety, and sleep disorders, causes personal, family, and social losses, and lowers the individual's quality of life.

Among diseases caused by stress, depression refers to a psychological state of depressed mood characterized by feelings of sadness, hopelessness, and frustration. In other words, it refers to a condition that progresses from the normal emotions of “depression” and dysthymic disorder to major depressive disorder.

The main symptoms of depression include changes in appetite, weight, or sleep patterns, psychomotor agitation or retardation, decreased thinking ability, concentration, or decision-making ability, lack of energy and fatigue, feelings of worthlessness, and self-blame. or a major depressive episode, a period of low mood or loss of interest or pleasure in most activities, combined with feelings of guilt, frequent thoughts of death or suicide, or some of the following plans or attempts to commit suicide. It is characterized by

Brain-derived neurotrophic factor (BDNF) is a small dimeric protein that is one of the nerve growth promoting factors, and is widely expressed in the brain of grown mammals. BDNF is involved in the maintenance and development of the nervous system, and is known to play an important role in the regulation of neurotransmitters and neuroplasticity. Therefore, the association between BDNF and neurological or psychiatric diseases has been studied by several researchers, and several recent studies have shown that BDNF genetic polymorphisms are associated with schizophrenia, biphasic disorder, depression, and obsessive-compulsive disorder. It has been reported.

In particular, it has been reported that chronic stress causes damage and atrophy of the hippocampus in animal models, and that damage to the hippocampus is related to decreased expression of BDNF, suggesting that BDNF influences the pathophysiological mechanism of depression. Several research results have been reported on the role of . Karege et al. (2002) found that BDNF concentration was lower in the major depression patient group compared to the normal control group.

According to depression treatment statistics recently announced by the National Health Insurance Corporation, the number of patients with depression increased by 12.4% in 2011 compared to 2007, and looking at the current status by type of suicide cause from 2009 to 2010, suicide due to mental and psychiatric problems is the 1st cause of suicide. As shown above, the number of people who committed suicide for this reason shows an increasing trend, reaching 4,132 people (28.1%) in 2009 and 4,357 people (29.5%) in 2010. In addition to depression, the number of patients with ADHD (Attention Deficit/Hyperactivity Disorder) also increased by 9,000 over 5 years from 48,000 in 2007 to 57,000 in 2012, showing an average annual increase rate of 4.4%. .

Therefore, there is a need for extracts from natural products that can quickly improve, prevent, or treat depression caused by stress, and are safe and have no side effects.

Republic of Korea Patent Publication No. 2022-0019730 Republic of Korea Patent Publication No. 2021-0084942

The purpose of the present invention is to provide a food composition that can improve or prevent depression by containing loquat tree fruit extract as an active ingredient.

In addition, another object of the present invention is to provide a pharmaceutical composition that can prevent or treat depression by containing loquat tree fruit extract as an active ingredient.

The food composition for improving or preventing depression of the present invention to achieve the above object may contain loquat tree fruit extract as an active ingredient.

The food composition for improving or preventing depression may be a food composition for improving or preventing depression caused by stress.

The loquat fruit extract may be extracted with water, lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixed solvent thereof.

The lower alcohol having 1 to 4 carbon atoms may be 20 to 80% methanol, ethanol, butanol, or propanol.

After consuming the food composition, sucrose intake may be 70 to 85%.

The immobility time during forced swimming after ingesting the food composition may be 50 to 80 seconds.

When measured using the tail suspension method after ingesting the food composition, the immobility time may be 70 to 100 seconds.

The time spent on the rotarod after ingesting the food composition may be 110 to 150 seconds.

In addition, the pharmaceutical composition for preventing or treating depression caused by stress of the present invention to achieve the above-mentioned other purposes may contain loquat tree fruit extract as an active ingredient.

The composition for improving, preventing or treating depression containing the loquat fruit extract of the present invention as an active ingredient is non-toxic and has an excellent effect on improving, preventing or treating depression caused by stress, making it a competitive food composition and pharmaceutical composition. Effective in manufacturing.

Figure 1 is a graph showing sucrose preference in the normal group, control group, IMI group, Example 1 group, and Comparative Example 1 group.
Figure 2 is a graph showing the FST immobility time of the normal group, control group, IMI group, Example 1 group, and Comparative Example 1 group.
Figure 3 is a graph showing the TST immobility time of the normal group, control group, IMI group, Example 1 group, and Comparative Example 1 group.
Figure 4 is a graph measuring the time the normal group, control group, IMI group, Example 1 group, and Comparative Example 1 group stayed on the rotarod rail.

The present invention relates to a composition that can improve, prevent, or treat depression caused by stress by containing loquat tree fruit extract as an active ingredient.

Hereinafter, the present invention will be described in detail.

The composition of the present invention that can improve, prevent, or treat depression caused by stress contains loquat tree fruit extract as an active ingredient.

The loquat tree ( Eriobotrya japonica ) is an evergreen tree of the Rosaceae family. The leaves are called loquat leaves and have been used as folk remedies for their purifying, antitussive, expectorant, and diuretic effects, and the fruits are edible. Loquat fruit or leaf extracts have been reported to have various physiological activities such as antioxidant, anti-inflammatory, anticancer, and antiviral through various in vivo and in vitro experiments. In particular, the leaf extract contains amyloid beta (A β ), which is effective in reducing cognitive function. It was reported that the mouse's behavior was significantly improved.

The loquat fruit is mixed with the extraction solvent at a weight ratio of 1:5 to 25, preferably 1:8 to 15, extracted at 80 to 110 ° C. for 5 to 15 hours, preferably 7 to 10 hours, and then extracted for 50 hours. The extract is prepared by performing reduced pressure concentration at 60°C. If the weight ratio of the loquat tree fruit and the extraction solvent is outside the above range, the active ingredient of the loquat tree fruit may be extracted in a small amount in the extract.

If the extraction temperature is below the above lower limit, the active ingredients of the loquat tree fruit may be extracted in a small amount, and if the extraction temperature is above the above upper limit, toxic substances may be generated.

The extraction solvent for extracting each of the above extracts is water, lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixed solvent thereof. The lower alcohol may include 20 to 80% methanol, ethanol, butanol, or propanol.

The extraction solvent is not particularly limited, but extracts extracted with a 20 to 80% aqueous ethanol solution are preferred for improving, preventing or treating depression caused by stress.

It was confirmed that when the loquat tree fruit extract of the present invention is ingested, sucrose intake increases to 70 to 85%, preferably 72 to 78%, thereby acting preferably in improving, preventing or treating stress or depression.

In addition, when the loquat fruit extract of the present invention is ingested, the immobility time during forced swimming is shortened to 50 to 80 seconds, preferably 60 to 75 seconds, and the immobility time when measured by the tail suspension method is shortened to 50 to 80 seconds, preferably 60 to 75 seconds. It is short, 70 to 100 seconds, preferably 75 to 95 seconds, and the time spent on the rotarod is long, 110 to 150 seconds, preferably 120 to 140 seconds, so it is preferable for improving, preventing or treating depression caused by stress. It was confirmed that it worked.

The term ‘extract’ used in this specification when referring to loquat tree fruit includes not only the crude extract obtained by treatment with an extraction solvent, but also processed products of the loquat tree fruit extract. For example, loquat fruit extract can be prepared in powder form by additional processes such as reduced pressure distillation and freeze-drying or spray-drying.

In addition, the loquat tree fruit extract of the present invention, in a broad sense, also includes loquat tree fruit processed products formulated so that the loquat tree fruit can be administered to animals, such as loquat tree fruit powder. Although experiments were conducted with loquat tree fruit in the present invention, those skilled in the art would be able to predict that the desired effect can be achieved even in the form of a loquat tree fruit processed product.

Meanwhile, in this specification, the term ‘containing as an active ingredient’ means containing a sufficient amount to achieve the efficacy or activity of the loquat tree fruit extract. For example, the loquat fruit extract is used at a concentration of 10 to 1500 μg/ml, preferably 100 to 1000 μg/ml. Since the loquat tree fruit extract is a natural product and has no side effects on the human body even when administered in excessive amounts, the upper quantitative limit of the loquat tree fruit extract contained in the composition of the present invention can be selected within an appropriate range by a person skilled in the art.

The pharmaceutical composition of the present invention can be prepared using pharmaceutically suitable and physiologically acceptable auxiliaries in addition to the active ingredients, and the auxiliaries include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, Lubricants or flavoring agents can be used.

For administration, the pharmaceutical composition may be preferably formulated as a pharmaceutical composition containing one or more pharmaceutically acceptable carriers in addition to the active ingredients described above.

The pharmaceutical composition may be in the form of granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops, or injectable solutions. For example, for formulation in the form of tablets or capsules, the active ingredient may be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, etc. Additionally, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tracacance or sodium oleate, sodium stearate, magnesium stearate, sodium Includes benzoate, sodium acetate, sodium chloride, etc. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, etc.

Acceptable pharmaceutical carriers for compositions formulated as liquid solutions include those that are sterile and biocompatible, such as saline solution, sterile water, Ringer's solution, buffered saline solution, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these ingredients can be mixed and used, and other common additives such as antioxidants, buffers, and bacteriostatic agents can be added as needed. In addition, diluents, dispersants, surfactants, binders, and lubricants can be additionally added to formulate injectable formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.

Furthermore, it can be preferably formulated according to each disease or ingredient using a method disclosed by Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, as an appropriate method in the field.

The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., and is preferably administered orally. .

The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity. Usually, a skilled physician can easily determine and prescribe an effective dosage for the desired treatment or prevention. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g/kg.

The pharmaceutical composition of the present invention can be prepared in unit dosage form by formulation using a pharmaceutically acceptable carrier and/or excipient, or can be prepared by placing it in a multi-dose container. At this time, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet, or capsule, and may additionally contain a dispersant or stabilizer.

In addition, the present invention provides a food composition for improving, preventing, or treating depression caused by stress, containing loquat tree fruit extract as an active ingredient.

The food composition according to the present invention can be formulated in the same way as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meat, chocolate, pizza, ramen, other noodles, gum, ice cream, vitamin complexes, and health supplements. etc.

The food composition of the present invention may contain not only loquat tree fruit extract as an active ingredient, but also ingredients commonly added during food production, including, for example, proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents. do. Examples of the above-mentioned carbohydrates include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, oligosaccharides, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is manufactured as a drink or beverage, in addition to the loquat tree fruit extract of the present invention, citric acid, high fructose corn syrup, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be additionally included. there is.

The present invention provides a health functional food containing a food composition for improving, preventing, or treating depression caused by stress, containing the loquat tree fruit extract as an active ingredient. Health functional foods are foods manufactured by adding loquat fruit extract to food ingredients such as beverages, teas, spices, gums, and confectionery, or by encapsulating, powdering, or suspending them, and have specific health effects when consumed. However, unlike regular drugs, it has the advantage of not having any side effects that may occur when taking the drug for a long time since it is made from food. The health functional food of the present invention obtained in this way is very useful because it can be consumed on a daily basis. The amount of loquat fruit extract added in such health functional foods cannot be uniformly specified as it depends on the type of health functional food being targeted, but it can be added within the range that does not damage the original taste of the food. It is usually in the range of 0.01 to 50% by weight, preferably 0.1 to 20% by weight. In addition, in the case of health functional foods in the form of pills, granules, tablets, or capsules, it is usually added in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule, or beverage.

In addition, the present invention provides the use of loquat fruit extract for the production of medicine or food for improving, preventing, or treating depression caused by stress. As mentioned above, loquat fruit extract can be used to improve, prevent, or treat depression caused by stress.

Additionally, the present invention provides a method for improving, preventing, or treating depression caused by stress, comprising administering an effective amount of loquat fruit extract to a mammal.

As used herein, the term “mammal” refers to a mammal, preferably a human, that is the subject of treatment, observation or experiment.

As used herein, the term “effective amount” means the amount of an active ingredient or pharmaceutical composition that is believed by a researcher, veterinarian, physician, or other clinician to induce a biological or medical response in a tissue system, animal, or human, which means that It includes amounts that induce relief of symptoms of a disease or disorder. The effective amount and frequency of administration of the active ingredient of the present invention may vary depending on the desired effect. Therefore, the optimal dosage to be administered can be easily determined by a person skilled in the art, and can be determined based on the type of disease, the severity of the disease, the content of the active ingredient and other ingredients contained in the composition, the type of dosage form, and the patient's age, weight, and general health. It can be adjusted according to various factors, including condition, gender and diet, administration time, administration route and secretion rate of the composition, treatment period, and concurrently used drugs. In the prevention, treatment or improvement method of the present invention, in adults, the mixed extract of Mokdanpi, Baekbokryeong, Taxa and Salvia Salvia is administered at a dose of 0.001 g/kg to 10 g/kg once or several times a day. It is desirable.

In the treatment method of the present invention, the composition containing the loquat tree fruit extract as an active ingredient is administered through conventional routes through oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular or intradermal routes. It can be administered in any way.

Hereinafter, preferred embodiments are presented to aid understanding of the present invention. However, the following examples are merely illustrative of the present invention, and it is clear to those skilled in the art that various changes and modifications are possible within the scope and spirit of the present invention. It is natural that such variations and modifications fall within the scope of the attached patent claims.

Example 1.

Loquat fruit (seeds removed) and 70% ethanol aqueous solution were mixed at a weight ratio of 1:10 and extracted under reflux at 80°C for 8 hours to obtain loquat fruit extract.

Comparative Example 1.

Loquat tree leaves and 70% ethanol aqueous solution were mixed at a weight ratio of 1:10 and extracted under reflux at 80°C for 8 hours to obtain loquat leaf extract.

<Test example>

Prepared in Examples and Comparative Examples After filtering the extract, the filtrate was concentrated under reduced pressure below 60°C and used.

animal testing

ICR mice (5 weeks old, Coretech, Korea, male) weighing 20 to 25 g were used in the experiment. They were raised in acrylic cages (45 And constant temperature (20-24 ℃) and humidity (45-65%) were maintained. We monitored them for a week to help them adapt to the changed environment, maintained their sleep cycle, and checked for abnormal behavior.

The animal protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of the Korea Food Research Institute.

The experimental animals were selected only from healthy animals with consistent body weight changes, and were randomly assigned to a normal group administered saline solution, a control group administered the stress hormone corticosterone (CORT), and a control group administered corticosterone (CORT). After administration, a group administered imipramine, a conventional antidepressant, a sample group administered the extract of Example 1 after administration of corticosterone (CORT), and Comparative Example 1 after administration of corticosterone (CORT) The samples were divided into groups administered the extract, and 5 animals were used in each experimental group.

In an experiment using an animal model, stress hormone (corticosteron, CORT) was injected subcutaneously at a concentration of 40 mg/kg every day for a total of 21 days. Excessive administration of stress hormones (corticosteron, CORT) induces HPA-axis dysfunction, resulting in behavioral symptoms similar to depression. This ‘CORT-induced depressive-like behavior model’ is an experimental animal model mainly used to evaluate the efficacy of functional materials in improving depression.

-5 groups of mice-

Normal group: 5 animals administered saline solution

Control group: 5 rats administered stress hormone (corticosteron, CORT)

IMI group (positive control group): After stress hormone (corticosteron, CORT) administration, imipramine, a conventional antidepressant, was administered orally at 30 mg/kg.

Example Group 1: Oral administration of 300 mg/kg of the extract of Example 1 after administration of stress hormone (corticosteron, CORT)

Comparative Example Group 1: Oral administration of 300 mg/kg of extract of Comparative Example 1 after administration of stress hormone (corticosteron, CORT)

Test Example 1. Measurement of sucrose preference test

Sucrose intake is a representative indicator of anhedonia response, which is one of the symptoms of stress or depression, and in mice showing depression-like behavior, sucrose preference is significantly lower.

Figure 1 is a graph showing sucrose preference in the normal group, control group, IMI group, Example 1 group, and Comparative Example 1 group.

As shown in Figure 1, it was confirmed that the preference for sucrose in Example 1 group was significantly increased compared to the control group and Comparative Example 1 group, and this was confirmed to be similar to the IMI group administered an antidepressant.

On the other hand, it was confirmed that Comparative Example Group 1 showed a lower preference for sucrose than the control group.

Test Example 2. Immobility time measurement

An antidepressant experiment on avoidance ability in emergency situations was conducted from a behavioral pharmacology perspective through a forced swimming experiment.

To measure the forced swim test (FST), a transparent beaker over 30 cm high was filled with 15 cm of water (temperature 23-25°C), mice were brought in, and forced to swim for 6 minutes. They were captured and recorded as digital video files for 6 minutes, and immobility and swimming times were analyzed using a behavior analysis program (SMART v3.0, Panlab SL, Barcelona, Spain). Each result was analyzed based on the immobility time and swimming time when the mouse remained motionless on the water for the remaining 4 minutes excluding the first 2 minutes.

Figure 2 is a graph showing the FST immobility time of the normal group, control group, IMI group, Example 1 group, and Comparative Example 1 group.

As shown in Figure 2, it was confirmed that Example 1 group had a significant decrease in immobility time and an increase in swimming time compared to the control group and Comparative Example 1 group, which is normal. group and significantly decreased compared to the IMI group.

Accordingly, it was confirmed that the loquat tree fruit extract (Example 1) was more effective in antidepressant treatment than the loquat tree leaf extract.

Test Example 3. TST immobility time measurement_tail suspension method

After inducing stress, tape was attached to the end of the rat's tail, which was stabilized using a tail suspension test (Bioseb) device, and was hung upside down on the wall. Movement was observed for a total of 7 minutes, and the level of stress, etc., was measured by measuring the time the subject remained immobile.

When mice develop depression-like behavior, TST immobility time significantly increases.

Figure 3 is a graph showing the TST immobility time of the normal group, control group, IMI group, Example 1 group, and Comparative Example 1 group.

As shown in Figure 3, it was confirmed that the immobility time of Example 1 group was significantly reduced compared to the control group and Comparative Example 1 group.

The Example 1 group was confirmed to have similar depression alleviating efficacy as the IMI group.

Test Example 4. Rotarod measurement

Using the Rotarod test, we attempted to measure behavioral disorders such as hypokinesia in a mouse model of depression by administering stress hormones (corticosteron, CORT) and measure the depression-alleviating efficacy of the extract of Example 1.

Specifically, mice were assessed for sensorimotor coordination with a rotarod 1 day after the last CORT injection. The rotarod apparatus (Ugo Basile, Comerio Varese, Italy) consisted of a rotating spindle with a diameter of 3 cm and five individual compartments that allowed testing five mice simultaneously. After administration, the subjects were trained at a rotation speed of 4 rpm on the first day and 20 rpm on the second day. Then, on the third day, the experiment was performed at 25 rpm, and the falling time was measured. The practice was conducted twice at 5-minute intervals with a time limit of 300 seconds each, and the main experiment was conducted three times at 5-minute intervals and the average value was used.

Figure 4 is a graph measuring the time the normal group, control group, IMI group, Example 1 group, and Comparative Example 1 group stayed on the rotarod rail.

When an experimental animal exhibits depression-like behavior, the time the mouse stays on the rotarod rail is significantly reduced, which means a decrease in exercise capacity that occurs due to depression-like behavior.

As shown in Figure 4, it was confirmed that the time spent on the rotarod rail in Example 1 group was significantly increased compared to the control group and Comparative Example 1 group, which was also confirmed to be significantly increased compared to the IMI group.

This means that the extract of Example 1 has antidepressant efficacy.

Below, a formulation example of a composition containing the powder of the present invention is described, but the present invention is not intended to be limited, but merely explained in detail.

Formulation Example 1. Preparation of powder

500 mg of extract powder obtained in Example 1

100 mg lactose

Talc 10 mg

The above ingredients are mixed and filled into an airtight bubble to prepare a powder.

Formulation Example 2. Preparation of tablets

300 mg of extract powder obtained in Example 1

Corn starch 100 mg

100 mg lactose

Magnesium stearate 2 mg

After mixing the above ingredients, tablets are manufactured by compressing them according to a typical tablet manufacturing method.

Formulation Example 3. Preparation of capsules

200 mg of extract powder obtained in Example 1

3 mg crystalline cellulose

Lactose 14.8 mg

Magnesium stearate 0.2 mg

Capsules are prepared by mixing the above ingredients and filling them into gelatin capsules according to a typical capsule manufacturing method.

Formulation Example 4. Preparation of injection

600 mg of extract powder obtained in Example 1

Mannitol 180 mg

Sterile distilled water for injection 2974 mg

Na ₂ HPO _4, 12H ₂ O 26 mg

It is prepared with the above ingredients per ampoule according to the usual manufacturing method for injections.

Formulation Example 5. Preparation of liquid formulation

4 g of extract powder obtained in Example 1

10 g isomerized sugar

5 g mannitol

Proper amount of purified water

According to the usual liquid preparation method, add and dissolve each ingredient in purified water, add an appropriate amount of lemon flavor, mix the above ingredients, add purified water, adjust the total to 100g by adding purified water, and then fill it in a brown bottle and sterilize it. to produce a liquid.

Formulation Example 6. Preparation of granules

1,000 mg of extract powder obtained in Example 1

Vitamin mixture dosage

Vitamin A acetate 70 μg

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

Vitamin B6 0.5 mg

Vitamin B12 0.2 ㎍

Vitamin C 10 mg

Biotin 10 μg

Nicotinamide 1.7 mg

Folic acid 50 μg

Calcium pantothenate 0.5 mg

Mineral mixture appropriate amount

Ferrous sulfate 1.75 mg

Zinc oxide 0.82 mg

Magnesium carbonate 25.3 mg

Monobasic Potassium Phosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

The composition ratio of the above vitamin and mineral mixture is a mixture of components relatively suitable for granules in a preferred embodiment, but the mixing ratio may be modified arbitrarily. The above components are mixed according to a typical granule manufacturing method, and then the granules are mixed. It can be prepared and used to manufacture a health functional food composition according to a conventional method.

Formulation Example 7. Preparation of functional beverage

1,000 mg of extract powder obtained in Example 1

1,000 mg citric acid

100 g oligosaccharides

2 g plum concentrate

1 g taurine

Add purified water to make a total of 900 mL.

After mixing the above ingredients according to a typical health drink manufacturing method, stirring and heating at 85°C for about 1 hour, the resulting solution was filtered, placed in a sterilized 2 L container, sealed, sterilized, stored in the refrigerator, and then refrigerated. Used for manufacturing the functional beverage composition of the invention.

The composition ratio is a preferred embodiment of mixing ingredients relatively suitable for beverages of preference, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as demand class, country of demand, and intended use.

Claims (10)

A food composition for improving or preventing depression, comprising an extract of loquat ( Eriobotrya japonica ) fruit as an active ingredient. The food composition for improving or preventing depression according to claim 1, wherein the food composition for improving or preventing depression improves or prevents depression caused by stress. The food composition for improving or preventing depression according to claim 1, wherein the loquat fruit extract is extracted with water, lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixed solvent thereof. The food composition for improving or preventing depression according to claim 3, wherein the lower alcohol having 1 to 4 carbon atoms is 20 to 80% methanol, ethanol, butanol, or propanol. The method of claim 3, wherein the loquat fruit extract is a mixture of loquat fruit and an extraction solvent at a weight ratio of 1:5 to 25 and extracted at 80 to 110° C. for 5 to 15 hours. Improvement or prevention of depression. For food composition. The food composition for improving or preventing depression according to claim 1, wherein the sucrose intake after ingestion of the food composition is 70 to 85%. The food composition for improving or preventing depression according to claim 1, wherein the immobility time during forced swimming after ingestion of the food composition is 50 to 80 seconds. The food composition for improving or preventing depression according to claim 1, wherein the immobility time is 70 to 100 seconds when measured by the tail suspension method after ingestion of the food composition. The food composition for improving or preventing depression according to claim 1, wherein the time spent on the rotarod after ingestion of the food composition is 110 to 150 seconds. A pharmaceutical composition for preventing or treating depression, characterized in that it contains extract of loquat ( Eriobotrya japonica ) fruit as an active ingredient.